Table 2. Sensitizing effect of the TAT-RasGAP317-326 toward childhood tumors.
| Cell line | Tumor type | Chemotherapy | IC 50 (without peptide) | IC 50 (with 10 μM TAT-RasGAP 317-326 ) | Effect of TAT-RasGAP 317-326 on IC 50 |
|---|---|---|---|---|---|
| THP-1 | AML | 4-HC [μM] | 38 | 25 | Decrease |
| Etoposide [μg/ml] | >20 | 10 | Decrease | ||
| Vincristine [μM] | >10 | >10 | - | ||
| Doxorubicin [μg/ml] | 0.3 | 0.3 | No change | ||
| M-07e | AML | 4-HC [μM] | 20 | 11 | Decrease |
| Etoposide [μg/ml] | >150 | 150 | Decrease | ||
| Vincristine [μM] | >10 | 1 | Decrease | ||
| Doxorubicin [μg/ml] | 2 | 2 | No change | ||
| CEM | T-ALL | 4-HC [μM] | 25 | 12.5 | Decrease |
| Etoposide [μg/ml] | >100 | 25 | Decrease | ||
| Vincristine [μM] | >10 | >10 | - | ||
| Doxorubicin [μg/ml] | >10 | >10 | - | ||
| EW-11 | Ewing sarcoma | 4-HC [μM] | 40 | 35 | Decrease |
| Etoposide [μg/ml] | >200 | >200 | - | ||
| Vincristine [μM] | >10 | >10 | - | ||
| Doxorubicin [μg/ml] | 3 | 1 | Decrease | ||
| A673 | Ewing sarcoma | 4-HC [μM] | 20 | 10 | Decrease |
| Etoposide [μg/ml] | >200 | >200 | - | ||
| Vincristine [μM] | >10 | >10 | - | ||
| Doxorubicin [μg/ml] | 2 | 0.4 | Decrease | ||
| TC252 | Ewing sarcoma | 4-HC [μM] | 27 | 10 | Decrease |
| Etoposide [μg/ml] | >200 | 25 | Decrease | ||
| Vincristine [μM] | >10 | >10 | - | ||
| Doxorubicin [μg/ml] | >10 | 3 | Decrease | ||
| NB1-NBM | Neuroblastoma | 4-HC [μM] | 27 | 27 | No change |
| Etoposide [μg/ml] | 25 | 1 | Decrease | ||
| Vincristine [μM] | 10 | 0.04 | Decrease | ||
| Doxorubicin [μg/ml] | 0.3 | 0.07 | Decrease | ||
| NB1-FBS | Neuroblastoma | 4-HC [μM] | 10 | 3 | Decrease |
| Etoposide [μg/ml] | 2.5 | 1 | Decrease | ||
| Vincristine [μM] | >10 | >10 | - | ||
| Doxorubicin [μg/ml] | >10 | >10 | - | ||
| NB1-FBS-Re | Neuroblastoma | 4-HC [μM] | 15 | 2.5 | Decrease |
| Etoposide [μg/ml] | 2.5 | 1 | Decrease | ||
| Vincristine [μM] | >10 | >10 | - | ||
| Doxorubicin [μg/ml] | 0.05 | 0.004 | Decrease | ||
| LAN-1 | Neuroblastoma | 4-HC [μM] | 26 | 24 | Decrease |
| Etoposide [μg/ml] | 200 | 50 | Decrease | ||
| Vincristine [μM] | 0.1 | 0.02 | Decrease | ||
| Doxorubicin [μg/ml] | 0.3 | 0.3 | No change |
This table summarizes the effect of TAT-RasGAP317-326 in combination with 4-HC, etoposide, vincristine or doxorubicin on the IC50 of the cell lines studied in this paper. IC50 were calculated for each chemotherapeutic agent in the absence or in the presence of 10 μM TAT-RasGAP317-326. AML, acute myeloid leukemia; T-ALL, T-acute lymphoblastic leukemia; 4-HC, 4-hydroperoxycyclophophamide.